Literature DB >> 8309970

Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats.

R Brandeis1, L Raveh, J Grunwald, E Cohen, Y Ashani.   

Abstract

This study examined the ability of pretreatment with human serum butyrylcholinesterase (HuBChE) to prevent soman-induced cognitive impairments. Behavioral testing was carried out using the Morris water maze task evaluating learning, memory, and reversal learning processes. Pretreatment with HuBChE significantly prevented the memory and reversal learning impairments induced by soman. A small deficiency in performance was observed only during part of the learning period in HuBChE-treated rats after administration of soman. Results support the contention that pretreatment alone with HuBChE is sufficient to increase survival and to prevent impairment in cognitive functioning following exposure to soman.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8309970     DOI: 10.1016/0091-3057(93)90218-i

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

Review 1.  Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.

Authors:  Charles W Schindler; Steven R Goldberg
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 2.  Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.

Authors:  Yvonne Rosenberg; Ashima Saxena
Journal:  Neuropharmacology       Date:  2020-05-19       Impact factor: 5.250

3.  LARGE SCALE PURIFICATION OF BUTYRYLCHOLINESTERASE FROM HUMAN PLASMA SUITABLE FOR INJECTION INTO MONKEYS; A POTENTIAL NEW THERAPEUTIC FOR PROTECTION AGAINST COCAINE AND NERVE AGENT TOXICITY.

Authors:  Oksana Lockridge; Lawrence M Schopfer; Gail Winger; James H Woods
Journal:  J Med Chem Biol Radiol Def       Date:  2005-07-01

4.  Development of a long-acting Fc-fused cocaine hydrolase with improved yield of protein expression.

Authors:  Xiabin Chen; Jing Deng; Xirong Zheng; Jinling Zhang; Ziyuan Zhou; Huimei Wei; Chang-Guo Zhan; Fang Zheng
Journal:  Chem Biol Interact       Date:  2019-04-12       Impact factor: 5.192

5.  Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Authors:  Noel D Johnson; Ellen G Duysen; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2009-03-20       Impact factor: 4.294

6.  Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin.

Authors:  Yue-Jin Huang; Paul M Lundy; Anthoula Lazaris; Yue Huang; Hernan Baldassarre; Bin Wang; Carl Turcotte; Mélanie Côté; Annie Bellemare; Annie S Bilodeau; Sandra Brouillard; Madjid Touati; Peter Herskovits; Isabelle Bégin; Nathalie Neveu; Eric Brochu; Janice Pierson; Duncan K Hockley; Douglas M Cerasoli; David E Lenz; Harvey Wilgus; Costas N Karatzas; Solomon Langermann
Journal:  BMC Biotechnol       Date:  2008-05-16       Impact factor: 2.563

7.  Sodium Ion Effect on Separation Of Butyrylcholinesterase from Plasma by Ion-Exchange Chromatography.

Authors:  A G Postoarca; M Ionescu; A Piperea-Sianu; I Sarbu; L G Hinescu
Journal:  Curr Health Sci J       Date:  2015-04-10

8.  Saracatinib, a Src Tyrosine Kinase Inhibitor, as a Disease Modifier in the Rat DFP Model: Sex Differences, Neurobehavior, Gliosis, Neurodegeneration, and Nitro-Oxidative Stress.

Authors:  Meghan Gage; Marson Putra; Logan Wachter; Kylie Dishman; Megan Gard; Crystal Gomez-Estrada; Thimmasettappa Thippeswamy
Journal:  Antioxidants (Basel)       Date:  2021-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.